Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$5.09−0.08 (-1.55%)

Close on Nov 13, 2026Market cap $198.19MP/E –Yield –

Entrada Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Entrada Therapeutics's price to sales ratio was 45.2× on Nov 11, 2026, against 6.4× a year earlier. Over the last 3 years it ranged from 1.3× to 58.6×, with a median of 3.4×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	45.2×	+38.8
2025	Dec 31, 2025	6.4×	+3.4
2024	Dec 31, 2024	3.0×	–

Where these numbers come from

Parsed from the XBRL in Entrada Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing